Affordable Access

Publisher Website

[Efficacy of intense pulsed light therapy in the treatment of Meibomian gland dysfunction-related severe dry eye].

  • Egri, S1
  • Van Hollebecke, I1
  • Guindolet, D1
  • Manenti, C1
  • Rougier, H1
  • Gabison, É1
  • Cochereau, I1
  • Doan, S2
  • 1 Service d'Ophtalmologie, Fondation Adolphe-de-Rothschild, Paris, France. , (France)
  • 2 Service d'Ophtalmologie, Fondation Adolphe-de-Rothschild, Paris, France. Electronic address: [email protected]. , (France)
Published Article
Journal francais d'ophtalmologie
Publication Date
Feb 01, 2021
DOI: 10.1016/j.jfo.2020.04.061
PMID: 33358077


Dry eye syndrome caused by Meibomian gland dysfunction (MGD) is a common disease in the general population and impairs quality of life. Intense Pulsed Light (IPL) has mainly been used in dermatology for the treatment of skin disorders, and more recently for MGD-related dry eye. The objective of our study is to evaluate the efficacy and tolerability of IPL with the E-Eye® device (E-Swin, Houdan, France) in severe MGD-related dry eye patients. This non-comparative study included 20 patients with MGD-related dry eye with a Break-Up Time (BUT)<10seconds, dry eye symptoms >30mm on a Visual Analog Scale (VAS), and failure of lid hygiene and artificial tears. Treatment consisted of 3 sessions of IPL on D0, D15, and D45 (5 flashes of 13J/cm2 per eye). The following parameters were assessed at each visit and at D75 : symptoms graded with a VAS and the Standard Patient Assessment of Eye Dryness questionnaire (SPEED), BUT, corneal fluorescein staining, Meibomian gland expression score, meibography, tear film lipid layer thickness by interferometry and the ocular scattering index by double-pass aberrometry (OQAS). Statistical analysis was performed on the eye most affected at baseline. We included 40 eyes of 20 patients, 15 female and 5 male, mean age 47±15 years (24 to 74 years). The symptoms rated by VAS were severe, averaging 69±25mm. After treatment, there was a statistically significant decrease in symptoms, with a 14mm VAS decrease (55±29mm at D75 versus 69mm at D0, P=0.048) and SPEED score of 3.4 (19.0±6mm versus 22.4±4.6, P=0.03). The number of expressible Meibomian gland ducts increased significantly (from 5.9 to 8.1, P=0.04), lid redness decreased (from 1.4 to 0.6, P=NS) and BUT improved (from 4.2 to 5.9, P=NS). Other parameters remained unchanged. Three patients (15%) complained of transient ocular burning after each treatment. IPL appears to be effective in improving signs and symptoms in patients with severe MGD-related dry eye, with a good safety profile. Its exact mechanism of action remains to be elucidated. Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Report this publication


Seen <100 times